Response of patients with amyotrophic lateral sclerosis to testosterone therapy: endocrine evaluation.
Four men with amyotrophic lateral sclerosis (ALS) were treated with 200 mg of intramuscular testosterone weekly. Endocrine evaluation, using a gonadotropin-releasing hormone infusion test, indicated the expected degree of suppression of pituitary luteinizing hormone and follicle-stimulating hormone production. These data suggest that testosterone's (androgen) interaction with its receptors in the hypothalamic-pituitary axis is normal in patients with ALS.
D000690:Amyotrophic Lateral Sclerosis / Q000097:blood / Q000188:drug therapy*; D005640:Follicle Stimulating Hormone / Q000032:analysis; D006801:Humans; D007986:Luteinizing Hormone / Q000032:analysis; D008875:Middle Aged; D013739:Testosterone / Q000627:therapeutic use*
D013739:Testosterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone